(RTTNews) - Hoth Therapeutics (HOTH) announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor as a treatment for obesity. The study, conducted in GDNF-transgenic models, showed that GDNF significantly reduces fat accumulation, enhances metabolism, and improves insulin sensitivity, even under high-fat diet conditions.
"The data suggest that GDNF-based therapies could offer an entirely new approach to obesity treatment—one that activates the body's natural metabolic processes to burn excess fat efficiently," said Robb Knie, CEO Hoth Therapeutics.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
